UK markets close in 3 hours 40 minutes

Evotec SE (0IRF.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
17.77-0.22 (-1.21%)
As of 11:16AM BST. Market open.
Full screen
Previous close17.99
Open17.69
Bid17.27 x 0
Ask18.16 x 0
Day's range17.55 - 17.81
52-week range17.07 - 45.38
Volume2,219
Avg. volume162,226
Market cap3.139B
Beta (5Y monthly)1.11
PE ratio (TTM)444.25
EPS (TTM)0.04
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program

    EQS-News: Evotec SE / Key word(s): MiscellaneousJust – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program 20.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS ANTI-PLAGUE MABS EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES Hamburg, Germany, 20 September 2022:Evotec SE (Frankfurt

  • EQS Group

    Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)

    DGAP-News: Evotec SE / Key word(s): MiscellaneousEvotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU) 16.09.2022 / 15:00 CET/CESTThe issuer is solely responsible for the content of this announcement. J.POD® TOULOUSE, FRANCE (EU) BRINGS A DISRUPTIVE, FLEXIBLY SCALABLE BIOLOGICS MANUFACTURING TECHNOLOGY TO THE REGION THE MANUFACTURING FACILITY IS EXPECTED TO BE OPERATIONAL IN H2 2024 Hamburg, Germany, 16 September 2022:Evotec SE (Frankfurt Stock Exchange: EVT, M

  • EQS Group

    Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany

    DGAP-News: Evotec SE / Key word(s): MiscellaneousEvotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany 25.08.2022 / 07:31 CET/CESTThe issuer is solely responsible for the content of this announcement. EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKIL